Cytophage Technologies Ltd.

CYTO

CA2328211081

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 15:59:30 2024-05-31 EDT			5-day change	1st Jan Change
0.49 ^CAD	+6.52%		+2.08%	-30.46%

05-27	Cytophage Technologies Ltd. Strengthens Board of Directors	CI
04-30	Cuspis Capital III Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Cuspis Capital III Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 29, 2023 at 06:32 pm

Cuspis Capital III Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net income was CAD 0.040696 million compared to net loss of CAD 0.758192 million a year ago.

Latest news about Cytophage Technologies Ltd.

Cytophage Technologies Ltd. Strengthens Board of Directors	05-27	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Cytophage Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Cytophage Technologies Ltd. Appoints Michael D. Cochrane as Newest Member of Board of Directors	04-16	CI
Cytophage Technologies Ltd. Provides Update on Bacteriophage Human Trial at The Ottawa Hospital	04-02	CI
Cytophage Technologies Ltd. Provides Update on Upcoming Product for Egg Production in Canada	02-12	CI
Cytophage Technologies Inc. completed the acquisition of Cuspis Capital III Ltd. (TSXV:CIII.P) in a reverse merger transaction.	02-01	CI
Cuspis Capital III Ltd. announced that it has received CAD 2.5 million in funding	12-21	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
Cytophage Technologies Ltd. announced that it expects to receive CAD 2.5 million in funding	11-05	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-27	CI
Cytophage Technologies Inc. entered into a letter of intent to acquire Cuspis Capital III Ltd. (TSXV:CIII.P) in a reverse merger transaction.	23-05-31	CI
Cytophage Technologies Inc. announced that it expects to receive $5 million in funding from Cuspis Capital III Ltd.	23-05-31	CI
Cuspis Capital III Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
Cuspis Capital III Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-30	CI
Cuspis Capital III Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-26	CI
Cuspis Capital III Ltd. has completed an IPO in the amount of CAD 5 million.	22-02-01	CI
Cuspis Capital III Ltd. has filed an IPO in the amount of CAD 5 million.	21-11-23	CI

Chart Cytophage Technologies Ltd.

Duration

Period

More charts

Company Profile

Cytophage Technologies Ltd. is a Canadian biotechnology company. The Company uses advanced molecular genetic techniques and synthetic biology to create bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria, the Company generates customized phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a phage-display methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is poultry health products offered by the Company.

Sector

Pharmaceuticals

Calendar

2024-06-24 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CYTOPHAGE TECHNOLOGIES LTD.	-30.46%	15.37M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+31.17%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+14.89%	240B
NOVARTIS AG	+9.25%	210B
ROCHE HOLDING AG	-5.15%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals

Cytophage Technologies Ltd.

Equities

CYTO

CA2328211081

Pharmaceuticals

Cuspis Capital III Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023

Latest news about Cytophage Technologies Ltd.

Chart Cytophage Technologies Ltd.

Company Profile

Income Statement Evolution

Sector Other Pharmaceuticals